Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Anne-Laure Désage, Camille Léonce, Aurélie Swalduz, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 47

Showing 26-50 of 47 citing articles:

How to manage KRAS G12C-mutated advanced non-small-cell lung cancer
Biagio Ricciuti, Alessia Mira, Elisa Andrini, et al.
Drugs in Context (2022) Vol. 11, pp. 1-11
Open Access | Times Cited: 9
Computational design and validation of effective siRNAs to silence oncogenic KRAS
Prasanna Srinivasan Ramalingam, Sivakumar Arumugam
3 Biotech (2023) Vol. 13, Iss. 11
Open Access | Times Cited: 5
A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol
Sogand Sadeghi, Ali A. Kiaei, Mahnaz Boush, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations
Andreas Saltos, Ben Creelan, Tawee Tanvetyanon, et al.
Lung Cancer (2023) Vol. 183, pp. 107313-107313
Closed Access | Times Cited: 4
Oncolytic virotherapy against lung cancer: key receptors and signaling pathways of viral entry
Wenxun Dong, Ying Luo, Daqian He, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
Saloni Mangal, Abhijit Debnath, Rupa Mazumder, et al.
All Life (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Strategies for Targeting KRAS: A Challenging Drug Target
Abdul Wadood, Amar Ajmal, Ashfaq Ur Rehman
Current Pharmaceutical Design (2022) Vol. 28, Iss. 23, pp. 1897-1901
Closed Access | Times Cited: 6
Tumor Molecular and Microenvironment Characteristics in EBV-Associated Malignancies as Potential Therapeutic Targets: Focus on Gastric Cancer
Aviva Atri-Schuller, Hassan Abushukair, Ludimila Cavalcante, et al.
Current Issues in Molecular Biology (2022) Vol. 44, Iss. 11, pp. 5756-5767
Open Access | Times Cited: 6
KRAS Inhibitors and Target Engagement Technology: From Undruggable to Druggable Targets in Cancer Therapeutics
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 5, pp. 752-754
Open Access | Times Cited: 5
Selective Metalation of Functionalized Quinazolines to Enable Discovery and Advancement of Covalent KRAS Inhibitors
Brett D. Allison, Xiaohu Deng, Lian‐Sheng Li, et al.
Organic Process Research & Development (2022) Vol. 26, Iss. 10, pp. 2926-2936
Closed Access | Times Cited: 4
The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy
Chun-Lu Shu, Yuling Liu
Cancer Management and Research (2022) Vol. Volume 14, pp. 3485-3492
Open Access | Times Cited: 4
RAS: Circuitry and therapeutic targeting
Gagandeep Singh, Neelam Thakur, Umesh Kumar
Cellular Signalling (2022) Vol. 101, pp. 110505-110505
Closed Access | Times Cited: 3
Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer
Anastasia Karachaliou, Ηλίας Κοττέας, Oraianthi Fiste, et al.
Cancers (2024) Vol. 16, Iss. 8, pp. 1447-1447
Open Access
Treatments that Target Cell Communication

(2024), pp. 109-182
Closed Access
ML‐Based Screening of miRNA Inhibitors and Intervention of lncRNA/miRNA/mRNA Axis in Oncogenic KRAS‐Associated Colorectal Cancer
Prasanna Srinivasan Ramalingam, Deepak B. Thimiri Govinda Raj, Murugan Subramanian, et al.
Advances in Public Health (2024) Vol. 2024, Iss. 1
Open Access
Targeted KRASG12Vdegradation elicits efficient and durable lung adenocarcinoma regressionin vivo
Alberto J. M. Martín, Inmaculada García-Peréz, Sonia San José, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis
Chang-Soo Seong, Chunzi Huang, Austin C. Boese, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Small-Molecule Inhibitor of the Oncogenic KRASG12C Mutant for the Treatment of Currently Incurable Cancer
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 5, pp. 767-769
Open Access | Times Cited: 1
Long-Awaited Small-Molecule Drug Candidate for Drugging the Next Undruggable KRASG12D Mutant in Cancer Therapy
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 5, pp. 773-774
Open Access | Times Cited: 1
Tumor Molecular and Microenvironment Characteristics in EBV-Associated Malignancies as Potential Therapeutic Targets: Focus on Gastric Cancer
Aviva Atri Schuller, Hassan Abushukair, Ludimila Cavalcante, et al.
(2022)
Open Access | Times Cited: 1
Pharmaceutical Research Based on the Structure of KRAS Protein—Research and Practice on Teaching Reform of Biochemistry Course
修恩 曹
Hans Journal of Biomedicine (2023) Vol. 13, Iss. 03, pp. 334-348
Closed Access
Rebiopsie tumorale : quand ? pour qui ? pourquoi ? comment ?
Vincent Fallet
Revue des Maladies Respiratoires Actualités (2023) Vol. 15, Iss. 2, pp. 2S121-2S129
Closed Access
Previous Page - Page 2

Scroll to top